TaiRx EBITDA per Employee
EBITDA per Employee of TaiRx (6580.TWO) as of Oct 16, 2026.
Get this data via API
Financial Data API
EBITDA per Employee
-TWD
Last updated:
EBITDA per Employee of TaiRx is 2026 - TWD. EBITDA per Employee of TaiRx was 2025 - TWD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
TaiRx Stock analysis
What does TaiRx do? TaiRx Inc, listed on the Taiwan Stock Exchange under ticker 6580.TWO with ISIN TW0006580004, is a biotechnology company based in Taipei City, Taiwan. The company operates within the Health Care sector, focusing on research and development of novel drug products for cancer treatment. TaiRx went public through an IPO on June 20, 2017. Its primary focus includes the development of cancer treatment drugs and sepsis adjuvant therapy drugs. The company's product portfolio includes CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, and TRX-105. Among these, CVM-1118 and Rexis are currently in clinical trials. Zelnite is distributed to domestic medical institutions at all levels through distributors. TaiRx maintains a corporate website at https://www.trx.com.tw/, where further information about its operations and products can be found. The company is engaged in the research and development of innovative pharmaceutical solutions, targeting significant unmet medical needs in oncology and sepsis treatment. TaiRx's activities are centered on advancing drug candidates through clinical development and commercialization within the Taiwanese market and potentially beyond. The company's operations are conducted from its headquarters in Taipei City, reflecting its commitment to contributing to the healthcare industry in Taiwan and globally. TaiRx is one of the most popular companies on Eulerpool.
Frequently Asked Questions about TaiRx stock
On Eulerpool you can find the complete historical development of EBITDA per Employee TaiRx since 2006 – with annual values, charts, and detailed analysis.
EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.
EBITDA per Employee's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's TaiRx historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Workforce — TaiRx
All Key Metrics — TaiRx
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth